This site is intended for healthcare professionals
News

FibroGen announces FDA advisory committee to review roxadustat NDA tentatively scheduled for July 15, 2021 for the treatment of anemia of chronic kidney disease.- FibroGen

Read time: 1 mins
Last updated:7th Apr 2021
Published:8th Apr 2021
Condition: Anaemia and CKD
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest